Cargando…

Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series

Clinical studies have shown that bismuth-containing quadruple therapy given twice a day for 10 to 14 days is effective and safe in the treatment of Helicobacter pylori infection in Sardinia. However, bismuth is no longer available in Italy. To report the effectiveness and tolerability of pantoprazol...

Descripción completa

Detalles Bibliográficos
Autores principales: Dore, Maria P., Soro, Sara, Rocchi, Chiara, Loria, Maria F., Bibbò, Stefano, Pes, Giovanni M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839865/
https://www.ncbi.nlm.nih.gov/pubmed/27082621
http://dx.doi.org/10.1097/MD.0000000000003411
_version_ 1782428204734087168
author Dore, Maria P.
Soro, Sara
Rocchi, Chiara
Loria, Maria F.
Bibbò, Stefano
Pes, Giovanni M.
author_facet Dore, Maria P.
Soro, Sara
Rocchi, Chiara
Loria, Maria F.
Bibbò, Stefano
Pes, Giovanni M.
author_sort Dore, Maria P.
collection PubMed
description Clinical studies have shown that bismuth-containing quadruple therapy given twice a day for 10 to 14 days is effective and safe in the treatment of Helicobacter pylori infection in Sardinia. However, bismuth is no longer available in Italy. To report the effectiveness and tolerability of pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg given b.i.d. (with the midday and evening meals) for 10 days supplemented with Lactobacillus reuteri (DSM 17938) 10(8) cfu/tablet once a day for 20 days in patients treated in a routine daily practice setting. H pylori infection was defined as a positive gastric histopathology and/or (13)C-Urea Breath Test (UBT) and/or stool antigen testing. Successful eradication was documented by (13)C-UBT, and/or stool antigen assay at least 4 weeks post-therapy. Compliance and side effects were recorded after completing treatment. A total of 45 patients (10 men, 35 women; mean age 52.6 years) have completed the treatment regimen with the success rate of 93% (95% confidence interval = 85–99%). Compliance was excellent. Side effects were absent or generally mild. Proton pump inhibitor-tetracycline-metronidazole-L reuteri therapy provided high eradication rates with few side effects and therefore can safely replace bismuth in H pylori treatment. Further studies are needed that include susceptibility testing.
format Online
Article
Text
id pubmed-4839865
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-48398652016-06-02 Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series Dore, Maria P. Soro, Sara Rocchi, Chiara Loria, Maria F. Bibbò, Stefano Pes, Giovanni M. Medicine (Baltimore) 4900 Clinical studies have shown that bismuth-containing quadruple therapy given twice a day for 10 to 14 days is effective and safe in the treatment of Helicobacter pylori infection in Sardinia. However, bismuth is no longer available in Italy. To report the effectiveness and tolerability of pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg given b.i.d. (with the midday and evening meals) for 10 days supplemented with Lactobacillus reuteri (DSM 17938) 10(8) cfu/tablet once a day for 20 days in patients treated in a routine daily practice setting. H pylori infection was defined as a positive gastric histopathology and/or (13)C-Urea Breath Test (UBT) and/or stool antigen testing. Successful eradication was documented by (13)C-UBT, and/or stool antigen assay at least 4 weeks post-therapy. Compliance and side effects were recorded after completing treatment. A total of 45 patients (10 men, 35 women; mean age 52.6 years) have completed the treatment regimen with the success rate of 93% (95% confidence interval = 85–99%). Compliance was excellent. Side effects were absent or generally mild. Proton pump inhibitor-tetracycline-metronidazole-L reuteri therapy provided high eradication rates with few side effects and therefore can safely replace bismuth in H pylori treatment. Further studies are needed that include susceptibility testing. Wolters Kluwer Health 2016-04-18 /pmc/articles/PMC4839865/ /pubmed/27082621 http://dx.doi.org/10.1097/MD.0000000000003411 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 4900
Dore, Maria P.
Soro, Sara
Rocchi, Chiara
Loria, Maria F.
Bibbò, Stefano
Pes, Giovanni M.
Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series
title Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series
title_full Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series
title_fullStr Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series
title_full_unstemmed Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series
title_short Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series
title_sort inclusion of lactobacillus reuteri in the treatment of helicobacter pylori in sardinian patients: a case report series
topic 4900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839865/
https://www.ncbi.nlm.nih.gov/pubmed/27082621
http://dx.doi.org/10.1097/MD.0000000000003411
work_keys_str_mv AT doremariap inclusionoflactobacillusreuteriinthetreatmentofhelicobacterpyloriinsardinianpatientsacasereportseries
AT sorosara inclusionoflactobacillusreuteriinthetreatmentofhelicobacterpyloriinsardinianpatientsacasereportseries
AT rocchichiara inclusionoflactobacillusreuteriinthetreatmentofhelicobacterpyloriinsardinianpatientsacasereportseries
AT loriamariaf inclusionoflactobacillusreuteriinthetreatmentofhelicobacterpyloriinsardinianpatientsacasereportseries
AT bibbostefano inclusionoflactobacillusreuteriinthetreatmentofhelicobacterpyloriinsardinianpatientsacasereportseries
AT pesgiovannim inclusionoflactobacillusreuteriinthetreatmentofhelicobacterpyloriinsardinianpatientsacasereportseries